Contents
WHO welcomes a historic decision by @Gavi to invest in the first #malaria vaccine (RTS,S) – a great step forward in helping prevent malaria in children at risk https://t.co/YQzoyp39EN pic.twitter.com/6tpyL6P6D7
— World Health Organization (WHO) (@WHO) December 2, 2021
The report warns that the situation remains precarious, especially in sub-Saharan Africa. A convergence of threats in the region poses an added challenge to disease control efforts.
These include Ebola outbreaks in DRC and Guinea, armed conflicts and flooding. At the same time, the document reiterates that the pandemic is not over, and the pace of economic recovery is uncertain. Without immediate and accelerated action, key 2030 targets of the WHO Global technical strategy for malaria will be missed, and additional ground may be lost.
Meeting global malaria targets
The strategy’s goals include a 90 per cent reduction in global malaria incidence and mortality rates by 2030. The report reiterated that this will require new approaches and intensified efforts aided by new tools and better implementation of existing ones.
This includes a stronger emphasis on equitable and resilient health systems and data-driven strategies.
The report also recommended the expanded use of the RTS,S malaria vaccine recommended by WHO in October. “the vaccine is feasible to deliver, is safe, has a public health impact and is cost-effective,” Dr Alonso said.
“As we speak GAVI is discussing opening up a window for investment in this malaria vaccine,” he added.
Funding ‘flatlined’
The analysis also emphasized that stepped-up investment is also essential. “Funding has flatlined” Dr. Alonso warned “We are about 50 per cent off what we believed the target should be for 2020”.
The report found that a total of $3.3 billion was invested globally in malaria control and elimination in 2020. This was against a target of $6.8 billion to reach global malaria targets.
Annual investments will need to more than triple by 2030 – to $10.3 billion per year, the report noted.